Norepinephrine Transporter Blockade, Autonomic Failure

Status Completed

Clinical Trial Summary

Atomoxetine, a selective norepinephrine transporter (NET) blocker, increases standing blood pressure and improves neurogenic orthostatic hypotension (NOH)-related symptoms to a greater extent than midodrine, the current standard of care. Atomoxetine could be a new therapeutic alternative for the treatment of NOH in patients with autonomic failure, particularly those with multiple system atrophy (MSA). The proposed study consists of an open-label, dose-optimization phase followed by a randomized, double-blind, placebo-controlled, 2x2 crossover phase.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02796209
Study type	Interventional
Source	NYU Langone Health
Contact
Status	Completed
Phase	Phase 2
Start date	May 2016
Completion date	May 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05923866` - A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy	Phase 2
Recruiting	`NCT02778607` - PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
Completed	`NCT01485549` - Oligomeric Alpha-synuclein in Multiple System Atrophy
Recruiting	`NCT03811808` - Multiple System Atrophy Multidisciplinary Clinic
Completed	`NCT04193527` - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients	Phase 3
Completed	`NCT01888185` - Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
No longer available	`NCT05086094` - Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)